Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes

Clinical Breast Cancer

Volumn 4, Issue SUPPL. 3, 2004, Pages

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Carboplatin; Cisplatin; Combination therapy; Emesis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; DOCETAXEL; DOPAMINE RECEPTOR BLOCKING AGENT; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CROSS RESISTANCE; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; FEASIBILITY STUDY; FREQUENCY ANALYSIS; HUMAN; IN VITRO STUDY; LEUKOPENIA; METASTASIS POTENTIAL; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; THROMBOCYTOPENIA; VOMITING;

EID: 1642415980     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.s.004     Document Type: Article

References (21)

1. Martin M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001; 2:190-208.
2. Gralla RJ. New agents, new treatment, and antiemetic therapy. Semin Oncol 2002; 29(Suppl 4):19-124.
3. Blackstein M, Vogel C, Ambinder R, et al. Phase II study of gemcitabine in patients with metastatic breast cancer. Oncology 2002; 62:2-8.
4. Possinger K, Kaufmann M, Coleman R, et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 1999; 10:155-162.
5. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 1995; 13:2731-2736.
6. Valerio M, Cicero G, Armata M, et al. Gemcitabine (G) in pretreated breast cancer (BC). Proc Am Soc Clin Oncol 2001; 20:51b (Abstract #1953).
7. Spielman M, Kalla S, Llombart-Cussac A, et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Eur J Cancer 1997; 33:S149.
8. Schmid P, Akrivakis K, Flath B, et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 1999; 10:625-631.
9. van Moorsel CJ, Veerman G, Bergmann AM, et al. Combination chemotherapy studies with gemcitabine. Semin Oncol 1997; 24:S17-23.
10. Achanta G, Pelicano H, Feng L, et al. Interaction of p53 and DNA-PK in response to nucleoside analogues: Potential role as a sensor complex for DNA damage. Cancer Res 2001; 61:8723-8729.
11. Nagourney R, Link J, Kunkel L, et al. Phase II trial of cisplatin (CDDP) & gemcitabine (DFDC) in heavily pretreated breast cancer. Proc Am Soc Clin Oncol 1998; 17:161a (Abstract #619).
12. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23:32-35.
13. Nagourney RA, Link JS, Blitzer JB, et al. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000; 18:2245-2249.
14. Chaudhry S, Abdel-Rahman H, Patil R, et al. Prospective phase II study of weekly cisplatin-gemcitabine in refractory metastatic breast cancer (RM-BC). Proc Am Soc Clin Oncol 2000; 19:111a (Abstract #430).
15. Burch P, Mailliard J, Hillman D, et al. Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer (MBC) and failure on prior chemotherapy: A North Central Treatment Group trial. Breast Cancer Res Treat 2000; 64:81 (Abstract #322).
16. Stemmler J, Wohlrab B, Bosse D, et al. Gemcitabine plus cisplatin intensively pretreated metastatic breast cancer: A phase II trial. Proc Am Soc Clin Oncol 2003; 22:73 (Abstract #291).
17. Ruiz G, de la Pena H, Meza F, et al. A phase II study of gemcitabine plus cisplatin in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2001; 20:60b (Abstract #1988).
18. Fcps S, Alauddin Z, Rehman E, et al. Gemcitabine and cisplatin combination chemotherapy as second-line treatment in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2003; 22:53 (Abstract #212).
19. Dorshow J, Tetef M, Margolin K, et al. Significant activity of gemcitabine (Gem) and cisplatin (DDP) in both heavily (H) and minimally (M)-pretreated metastatic breast cancer (MBC) patients (pts): A California Cancer Consortium/Loyola Univ. Chicago Trial. Proc Am Soc Clin Oncol 2000; 19:155a (Abstract #609H).
20. Xu B, Li K, Liu D. Phase II trial of gemcitabine and cisplatin in anthracycline-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 2003; 22:53 (Abstract #211).
21. Latini L, Torresi U, Valeri M, et al. Carboplatin-gemcitabine combination in anthracyclines-and/or taxanes-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 2003; 22:80 (Abstract #318).